• 1
    Eberhardt W, Bildat S, Korfee S. Combined modality therapy in NSCLC. Ann Oncol. 2000; 11 (Suppl 3): 8595.
  • 2
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995; 311: 899909.
  • 3
    Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 1993; 55: 13651374.
  • 4
    Pisters KMW, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol. 1993; 11: 17571762.
  • 5
    Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol. 1992; 10: 580586.
  • 6
    Burkes RL, Shepherd FA, Ginsberg RJ, et al. Induction chemotherapy with MVP in patients with stage IIIA (T1-3, N2, M0) unresectable non small cell lung cancer: the Toronto experience [abstract]. Proc Am Soc Clin Oncol. 2000; 19: A1941.
  • 7
    Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR, and the Cancer and Leukemia Group B Thoracic Surgery Group. A multiinstitutional phase II trimodality trial for stage IIIa (N2) non small cell lung cancer. J Thorac Cardiovasc Surg. 1995; 109: 473485.
  • 8
    Eberhardt W, Wilke H, Stamatis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non small cell lung cancer: mature results of a phase II trial. J Clin Oncol. 1998; 16: 622634.
  • 9
    Kumar P, Herndon J II, Langer M, et al. Patterns of disease failure after trimodality therapy of non small cell lung carcinoma pathologic stage IIIa (N2). Cancer. 1996; 77: 23932399.
  • 10
    Law A, Karp DD, Dipetrillo T, Daly B. Emergence of increased cerebral metastases after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced non small cell lung carcinoma. Cancer. 2001; 92: 160164.
  • 11
    Andre F, Grunenwald D, Pujol JL, et al. Pattern of relapse of N2 non small-cell lung carcinoma patients treated with preoperative chemotherapy. Should prophylactic cranial irradiation be reconsidered? Cancer. 2001; 91: 23942400.
  • 12
    Robnett TJ, Machtay M, Stevenson JP, Algazy KM, Hahn SM. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non small cell lung cancer. J Clin Oncol. 2001; 19: 13441349.
  • 13
    Carretta A, Chiesa G, Zannini P, et al. Surgery following neoadjuvant MPV chemotherapy (mitomycin, cisplatin, vinblastine) in locally advanced (IIIA and IIIB) non small cell lung Eur J Cardiothorac Surg. 1994; 8: 457461.
  • 14
    Ceresoli GL, Reni M, Chiesa G, Carretta A, Zannini P, Villa E. Multimodality therapy (MMT) in stage IIIA non-small cell lung cancer (NSCLC): long term results and pattern of relapse in resected patients. Lung Cancer. 1998; 21 (Suppl 1): S40.
  • 15
    Mountain CF. The new international staging system for lung cancer. Surg Clin North Am. 1987; 67: 925935.
  • 16
    Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 17101717.
  • 17
    Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37: 745751.
  • 18
    Figlin RA, Piantadosi S, Feld R and the Lung Cancer Study Group. Intracranial recurrence of carcinoma after complete surgical resection of stage I, II and III non-small-cell lung cancer. N Engl J Med. 1988; 318: 13001305.
  • 19
    Martini N, Burt ME, Bains MS, McCormack P, Rusch VW, Ginsberg RJ. Survival after resection of stage II non-small-cell lung cancer. Ann Thorac Surg. 1992; 54: 460466.
  • 20
    Thomas PA, Piantadosi S and the Lung Cancer Study Group. Postoperative T1N0 non-small-cell lung cancer, squamous versus nonsquamous recurrences. J Thorac Cardiovasc Surg. 1987; 94: 349354.
  • 21
    Perez CA, Pajac TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer. 1987; 59: 18741881.
  • 22
    Vora SA, Daly BDT, Blaszkowsky L, et al. High dose radiation therapy and chemotherapy as induction treatment for stage III non-small-cell lung carcinoma. Cancer. 2000; 89: 19461952.
  • 23
    Cox JD, Scott CB, Byhardt RW, et al. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small-cell carcinoma of lung (NSCLC): analysis of Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1999; 43: 505509.
  • 24
    Stuschke M, Eberhardt W, Pottgen C, et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long term follow-up and investigations of late neuropsychologic effects. J Clin Oncol. 1999; 17: 27002709.
  • 25
    D'Amico TA, Aloia TA, Moore MB, et al. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg. 2001; 72: 11441148.
  • 26
    Heinsius T, Bogousslavsky J, Van Melle G. Large infarcts in the middle cerebral artery territory. Etiology and outcome patterns. Neurology. 1998; 50: 341350.
  • 27
    Jacobs RH, Awan A, Bitran JD, et al. Prophylactic cranial irradiation in adenocarcinoma of the lung. A possible role. Cancer. 1987; 59: 20162019.
  • 28
    Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer. J Clin Oncol. 1997; 15: 712722.
  • 29
    Maurel J, Martinez-Trufero J, Artal A, et al. Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy. Lung Cancer. 2000; 30: 107116.
  • 30
    Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000; 18: 29812989.
  • 31
    Komaki R, Seiferheld W, Curran W, et al. Sequential versus concurrent chemotherapy and radiation therapy for inoperable non-small-cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410) [abstract]. Proc ASTRO. 2000; 48: A5.
  • 32
    Arriagada R, Le Chevalier T, Quoix E, et al. ASTRO plenary. Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study on 353 patients. Int J Radiat Oncol Biol Phys. 1991; 20: 11831190.
  • 33
    Mandell L, Hilaris B, Sullivan M, et al. The treatment of single brain metastasis from non-oat cell lung carcinoma. Cancer. 1986; 58: 641649.
  • 34
    Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999; 17: 26922699.
  • 35
    Komaki R, Scott C, Ettinger D, et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable non-small-cell lung cancer: RTOG 92-04. Int J Radiat Oncol Biol Phys. 1997; 38: 149155.
  • 36
    Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998; 42: 469478.
  • 37
    Yokoi K, Miyazawa N, Arai T. Brain metastases in resected lung cancer: value of intensive follow-up with computed tomography. Ann Thorac Surg. 1996; 61: 546551.
  • 38
    Yokoi K, Kamiya N, Matsuguma H, et al. Detection of brain metastases in potentially operable non-small cell lung cancer. A comparison of CT and MRI. Chest. 1999; 115: 714719.
  • 39
    Cox JD, Stanley K, Petrovich Z, Paig C, Yesner R. Cranial irradiation in cancer of the lung of all cell types. J Am Med Assoc. 1981; 245: 469472.
  • 40
    Griffin BR, Livingston RB, Stewart GR, et al. Prophylactic cranial irradiation for limited non-small cell lung cancer. Cancer. 1988; 62: 3639.
  • 41
    Russell AH, Pajak TE, Selim HM, et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1991; 21: 637643.
  • 42
    Umsawasdi T, Valdivieso M, Chen TT, et al. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol. 1984; 2: 253259.
  • 43
    Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol. 1999; 10: 753759.
  • 44
    Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2001; 53: 259265.
  • 45
    Schutte W, Manegold C, Von Pawel JV,et al. Topotecan: a new treatment option in the therapy of brain metastases of lung cancer. Front Radiat Ther Oncol. 1999; 33: 354363.